© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention
April 12, 2024
AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.
Novel Antiobesity Drug Significantly Improves Body Composition, Bone Mineral Content in Phase 2 Study
April 12, 2024
LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.
Consider CGRP Inhibitors as a First-Line Option for Preventive Treatment of Migraine: New American Headache Society Consensus Statement
April 12, 2024
The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.
RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research
April 11, 2024
In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.
Elevated Albuminuria, Even Within Normoalbuminuric Range, May Be Linked to Elevated Risk for CKD Progression, Renal Failure
April 10, 2024
New study findings raise important questions about how early to initiate therapy to reduce proteinuria and whether even lower levels should be sought to improve CKD outcomes.
Risk for CHD Double Among Women who Binge Drink vs Men
April 10, 2024
ACC.24: Even modest alcohol intake increases risk for coronary heart disease in men and women but women are at much greater risk across levels of weekly consumption.
Madrigal Announces US Availability of Resmetirom (Rezdiffra), First Patients Treated for NASH
April 09, 2024
Resmetirom to treat NASH with F2-F3 fibrosis, the only approved therapy, is available through Madrigal's specialty pharmacy network, the company said.
Novel Web Tool Determines Consumer Eligibility for OTC Statin, With High Clinician Concordance
April 09, 2024
The web app showed more than 90% concordance with clinical assessment of eligibility for low dose rosuvastatin; study yields 35.5% reduction in LDL-C.
Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD
April 09, 2024
Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.
Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
April 08, 2024
ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.